A bad tumor biomarker is as bad as a bad drug: The gap between genomics data and phenotype to predict response.

Abstract excerpt

The search for novel prognostic and predictive parameters in breast carcinoma is relentless. The new technological advances in gene expression profiling and in mutational analysis will hopefully prove to be clinically useful in informing the choice for the systemic therapy. For the time being, we are still relying in established immunohistochemical markers, namely estrogen and progesterone receptors, HER2 and...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Biomarkers, Tumor
• Share to Breast Neoplasms
• Share to Drug Resistance, Neoplasm